Pharvaris ($PHVS) Stock Hub: Deucrictibant, CHAPTER-3 and the HAE Franchise Thesis

1. Pharvaris Investor Snapshot

Pharvaris is a late-stage biotechnology company focused on bradykinin-mediated angioedema. Its entire current investment case is centered on deucrictibant, an orally bioavailable small-molecule antagonist of the bradykinin B2 receptor. The molecule is being developed in two formulations: an immediate-release capsule for treating attacks after they begin and an extended-release tablet for preventing attacks through once-daily prophylaxis.

The distinction matters because the company is not trying to build two unrelated products. It is attempting to establish a single active ingredient across both major treatment paradigms. If successful, a patient could potentially use deucrictibant XR for prevention and deucrictibant IR for breakthrough attacks. Pharvaris argues that this continuity could simplify patient experience and create a differentiated franchise. Investors should treat that as a strategic hypothesis until approvals, labels, reimbursement and real-world use confirm it.

2. Company Profile, Corporate Structure and History

Pharvaris N.V. was incorporated in 2015 and is organized under Dutch law. The company is based in Leiden, the Netherlands, with headquarters activity in Zug, Switzerland, and a U.S. presence in Lexington, Massachusetts. Its ordinary shares trade on the Nasdaq Global Select Market under the ticker PHVS. Pharvaris is a foreign private issuer and reports under International Financial Reporting Standards, with the euro as its reporting currency.

The scientific heritage is relevant. Members of the founding team were involved in the discovery and development of icatibant, the injected bradykinin B2 receptor antagonist that validated the target in acute HAE treatment. Pharvaris is attempting to retain the downstream B2-receptor mechanism while replacing the injection with an oral small molecule that can be formulated for either rapid or sustained exposure.

The company completed its initial public offering in 2021. Since then, its development path has included a major regulatory interruption: U.S. clinical studies were placed on hold in August 2022 after nonclinical toxicology findings in animals. The FDA lifted the holds in two separate stages: the on-demand IND in June 2023, after an interim analysis of a long-term rodent study, and the prophylaxis IND in January 2024, once the complete data set was available. That history should not be erased from the narrative. It demonstrates that the company has already experienced a material regulatory setback, completed additional work and returned both formulations to late-stage development. It also explains why investors should continue to monitor long-term safety and regulatory interpretation closely.

3. Hereditary Angioedema: Disease Burden and Market Context

Hereditary angioedema is a rare disorder characterized by recurrent, unpredictable episodes of swelling. Attacks can affect the extremities, face, abdomen, genitals and upper airway. Abdominal attacks can cause severe pain, nausea and vomiting. Laryngeal swelling can be life-threatening because it may obstruct the airway. Unlike histamine-mediated allergic swelling, classic HAE attacks are driven by excess bradykinin and generally do not respond to antihistamines, corticosteroids or epinephrine in the same way as ordinary allergic reactions.

HAE type I is usually associated with deficient levels of functional C1 inhibitor, while type II involves dysfunctional C1 inhibitor. A smaller and heterogeneous group has HAE with normal C1 inhibitor. The unpredictable timing of attacks creates a burden that extends beyond attack frequency: patients may delay travel, work, school or social activity because they cannot know where or when swelling will begin.

Treatment divides into two broad categories. On-demand treatment is taken when an attack begins, ideally as early as possible. Long-term prophylaxis is taken regularly to reduce attack frequency. Patients receiving prophylaxis still require access to rescue treatment because breakthrough attacks can occur. This dual requirement is the foundation of Pharvaris’ franchise strategy.

The market is attractive but no longer underdeveloped

HAE is a rare disease, yet it supports multiple high-value products because treatment is chronic, specialized and clinically necessary. Pharvaris’ presentation cites an internally sourced prediction of a U.S. HAE market reaching approximately $4.7 billion in 2036. That figure should be understood as a company-presented market estimate rather than an independently guaranteed outcome.

Competition has accelerated. The United States now has several effective prophylactic options, including injectable Takhzyro, oral Orladeyo, monthly ANDEMBRY and DAWNZERA, which can be dosed every four or eight weeks. The acute-treatment landscape includes C1 inhibitor products, injectable icatibant and oral EKTERLY. Deucrictibant therefore does not need merely to work; it needs a profile strong enough to win use in a market where patients and physicians already have credible choices.

4. Deucrictibant Science: Why the Bradykinin B2 Receptor Matters

Bradykinin increases vascular permeability by binding to the bradykinin B2 receptor. In HAE, excessive bradykinin signaling allows fluid to leave blood vessels and enter surrounding tissue, producing swelling. The contact-system pathway that generates bradykinin includes factor XII, plasma kallikrein and high-molecular-weight kininogen. Several competing products intervene upstream by inhibiting kallikrein, factor XIIa or prekallikrein production.

Deucrictibant acts downstream by blocking the B2 receptor itself. This approach is clinically validated by icatibant, which is approved for acute HAE attacks and is administered by subcutaneous injection. Pharvaris’ central scientific proposition is that a potent oral B2-receptor antagonist can deliver the target-level benefit of icatibant without injection burden.

The downstream mechanism may also be relevant beyond classic HAE types I and II. Because the receptor sits at the final signaling step, Pharvaris argues that it may work across bradykinin-mediated forms of angioedema regardless of which upstream pathway produces excess bradykinin. This is the rationale for including HAE with normal C1 inhibitor in RAPIDe-3 and for developing deucrictibant in acquired angioedema due to C1 inhibitor deficiency.

Mechanism strength does not guarantee formulation success

Investors should separate target validation from product validation. The B2 receptor is validated. Oral deucrictibant’s clinical profile still depends on absorption, exposure, duration, adherence, drug interactions, safety and manufacturing consistency. A valid mechanism can still produce a commercially mediocre product if the formulation does not achieve competitive exposure or if tolerability limits chronic use.

5. Pharvaris Pipeline Map

The pipeline appears broad because it contains four named programs, but all are based on the same active ingredient and mechanism. This creates operating leverage if deucrictibant succeeds: manufacturing knowledge, safety data, physician education and brand investment can support multiple uses. The same structure magnifies downside if an unexpected molecule-level safety issue emerges.

6. RAPIDe-3: The Positive Phase 3 Foundation

RAPIDe-3 was a global, randomized, double-blind, placebo-controlled crossover study evaluating deucrictibant IR for on-demand treatment of HAE attacks in patients aged 12 to 75. The study enrolled 134 participants from 24 countries on six continents. Eighty-eight participants generated the paired efficacy comparison in which one qualifying attack was treated with deucrictibant and another with placebo.

The crossover design is useful in a heterogeneous disease because each participant can contribute data under both treatment conditions. Attack location and severity can still differ, so the design does not eliminate all variability, but it reduces some between-patient noise.

Headline efficacy results

Pharvaris reported that RAPIDe-3 met the primary endpoint and all 11 secondary efficacy endpoints with statistical significance. The company also reported no treatment-related serious adverse events and no discontinuations due to treatment-emergent adverse events. These are strong results, but the current evidence remains largely company-sponsored and conference-presented. Regulatory review will test the full dataset, including missing data, attack adjudication, population heterogeneity, repeat dosing, exposure and manufacturing.

End of Progression: useful endpoint or marketing construction?

End of Progression is defined as the earliest timepoint after treatment after which all subsequent symptom-change ratings remain stable or improved through the specified assessment window. Clinically, the concept is intuitive: patients want to know when an attack has stopped getting worse. The very rapid 17.47-minute median is potentially meaningful because delayed treatment can allow attacks to become more severe.

However, End of Progression is a Pharvaris-defined and trademarked term. The FDA will decide how much weight it receives in labeling and promotional claims. Investors should focus first on accepted endpoints such as symptom relief, severity reduction, complete resolution and rescue-medication use. A fast EoP result supports differentiation, but it should not substitute for the broader efficacy package.

7. FDA Pathway and the April 23, 2027 PDUFA Date

On July 6, 2026, Pharvaris announced that the FDA accepted the New Drug Application for deucrictibant IR 20 mg capsules for on-demand treatment of HAE attacks in patients aged 12 and older. The agency assigned a PDUFA action date of April 23, 2027.

NDA acceptance means the FDA determined that the application was sufficiently complete for substantive review. It does not mean the agency has concluded that the drug is safe, effective, manufacturable or approvable. The review can still produce information requests, labeling negotiations, inspection issues, a delayed action date or a Complete Response Letter.

The company has orphan drug designation in the United States, European Union and Switzerland. Orphan designation can provide development incentives and, if the statutory requirements are met, market exclusivity after approval. It does not prevent competition from drugs with different active ingredients or mechanisms, and it does not guarantee that deucrictibant will receive approval.

8. CHAPTER-3: The Most Important Near-Term Catalyst

CHAPTER-3 is a global, randomized, double-blind, placebo-controlled Phase 3 trial of once-daily deucrictibant XR for prophylaxis against HAE attacks. Approximately 81 adults and adolescents aged 12 and older were randomized 2:1 to receive the intended commercial 40 mg XR formulation or placebo for 24 weeks. Enrollment is complete, the study is active but no longer recruiting, and Pharvaris expects topline data in the third quarter of 2026.

The primary question is the rate of investigator-confirmed HAE attacks during the treatment period. Additional measures include treatment-emergent adverse events, pharmacokinetics, attack severity, use of on-demand medication and health-related quality of life.

What a strong result should contain

• Clear statistical significance on the primary monthly attack-rate endpoint.
• A low absolute attack rate, not merely a favorable percentage reduction against a high placebo rate.
• Competitive attack-free rates over the six-month treatment period.
• Reductions in moderate or severe attacks and in attacks requiring rescue medication.
• Consistent benefit across relevant subgroups, including baseline attack frequency, age and geographic region.
• Clean chronic-use tolerability, with low discontinuation and no concerning cardiovascular, hepatic or laboratory pattern.
• Evidence that protection begins rapidly, supporting the company’s claim that steady state is achieved within two to three days.

Why a statistically positive readout could still disappoint

The market will compare deucrictibant with highly effective injectables and newer long-interval therapies. A positive trial with a modest absolute benefit could be commercially weak. Investors are likely to focus on whether once-daily oral convenience is paired with efficacy close enough to Takhzyro, DAWNZERA or ANDEMBRY to drive switching. If efficacy resembles the more modest profile historically associated with oral Orladeyo, the commercial differentiation may narrow.

Sample size is another sensitivity. Approximately 81 participants is reasonable for a rare-disease pivotal study, but subgroup analyses may be small and unstable. One or two participants with unusually high attack rates can influence the aggregate result. The full distribution, confidence intervals and treatment exposure will matter more than a single percentage headline.

9. CHAPTER-1: The Phase 2 Evidence Behind the Pivotal Bet

CHAPTER-1 was a randomized, placebo-controlled Phase 2 study in 34 adults with HAE type I or II. Participants received placebo, deucrictibant 20 mg per day or 40 mg per day for 12 weeks. The study used the immediate-release formulation dosed twice daily during the randomized phase, while CHAPTER-3 evaluates the intended once-daily extended-release commercial formulation.

At the 40 mg daily dose, Pharvaris reported an 84.5% reduction in mean monthly HAE attack rate versus placebo. The company also reported a 92.3% reduction in moderate or severe attacks and a 92.6% reduction in attacks requiring on-demand treatment versus placebo. The company reported no serious adverse events, no severe treatment-emergent adverse events and no adverse events leading to discontinuation. Severe attacks were absent in the placebo arm as well, so the absence of severe attacks on deucrictibant should not be read as a treatment effect: the quantified comparison is the 92.3% reduction in moderate or severe attacks.

Participants completing the randomized phase could enter a long-term open-label extension. Final extension data presented in 2026 showed an average reduction in attack frequency of approximately 92% from baseline, with about half of participants remaining attack-free throughout the extension. Treatment exposure extended to approximately 34 months for some participants before transition into CHAPTER-4.

Open-label extensions are useful for durability and safety but are vulnerable to selection bias. Patients who benefit and tolerate therapy are more likely to remain enrolled. Attack rates can also change over time. Therefore, the extension strengthens the case but cannot replace the blinded, placebo-controlled CHAPTER-3 result.

10. CHAPTER-4, CREAATE and the Broader Portfolio

CHAPTER-4 long-term extension

CHAPTER-4 is an open-label extension evaluating long-term once-daily deucrictibant XR. It enrols participants rolling over from CHAPTER-3 and earlier deucrictibant studies, and it can also enrol patients who have never received deucrictibant, so it is not a closed extension cohort. The data can support chronic-use safety, durability and patient-reported outcomes. Because prophylaxis may continue for years, the size and quality of the long-term exposure database will matter to regulators, physicians and payers.

CREAATE in acquired angioedema

CREAATE is a global pivotal Phase 3 study in acquired angioedema due to C1 inhibitor deficiency. Unlike hereditary disease, AAE-C1INH is acquired and can be associated with underlying lymphoproliferative or autoimmune conditions. The study includes prophylactic and on-demand components using the XR and IR formulations.

The commercial population is smaller than HAE, but the indication is underserved and mechanism-based. A successful program could expand the label and reinforce the idea that directly blocking the B2 receptor works across different sources of excess bradykinin. Investors should not assign the same near-term value to CREAATE as to CHAPTER-3 or the accepted NDA because enrollment and data timing are less immediate.

Beyond angioedema

Pharvaris and its scientific collaborators have discussed broader diseases in which bradykinin signaling may play a role, including chronic cough, asthma, allergic rhinitis and urticaria. These concepts are early and should be treated as optionality rather than current valuation pillars. Expanding into common inflammatory diseases would require substantial development, different trial designs and considerably more capital.

11. Commercial Opportunity: One Molecule, Two Treatment Settings

The most attractive version of the Pharvaris thesis is not simply “an oral attack drug” or “an oral prophylaxis tablet.” It is an integrated franchise in which one molecule can accompany patients across their disease journey. A patient with infrequent attacks might begin with deucrictibant IR on demand. If attack burden increases, the patient could move to daily XR prophylaxis while retaining IR for breakthrough attacks.

This could create familiarity and confidence in a single active ingredient. Physicians would already understand the mechanism and safety profile. Pharvaris could use a unified rare-disease commercial organization rather than building separate teams for unrelated assets. Manufacturing and medical affairs could also benefit from shared knowledge.

The commercial thesis depends on four separate wins

1. Regulatory approval: the IR capsule must clear FDA review, and XR must eventually produce a sufficient filing package.
2. Competitive labeling: the final indications, age ranges, dosing instructions and safety language must support use.
3. Payer access: oral convenience will not drive adoption if reimbursement requires failure of cheaper or established therapies.
4. Real-world behavior: patients must carry, take and trust the product early in attacks; prophylaxis patients must remain adherent to daily dosing.

Commercial preparation is already underway. The May 2026 financing was explicitly intended in part to fund expansion of the U.S. sales and marketing organization and launch preparation. This reduces execution risk compared with waiting until approval, but it also increases operating expenses before revenue is certain.

12. Competitive Landscape: What Deucrictibant Must Beat

The HAE market now contains strong therapies across multiple mechanisms and dosing schedules. A clean comparison requires separating on-demand treatment from prophylaxis.

On-demand competitors

EKTERLY changes the investment debate. It was approved in July 2025 and generated approximately $49.1 million of global net product revenue in the eight-month transition period ended December 31, 2025, reported in KalVista’s transition report filed on March 25, 2026. Because the drug launched on July 7, 2025, that figure covers roughly six months of actual selling rather than eight. It also accumulated more than 1,700 U.S. patient start forms by the end of February 2026. Deucrictibant will therefore enter an oral market with an incumbent, not create the category from zero.

Pharvaris will attempt to differentiate through a single-capsule profile, complete symptom resolution, rapid End of Progression and direct B2-receptor blockade. Cross-trial comparisons are unreliable because trial populations, endpoints and statistical methods differ. The real commercial comparison will require label review and real-world physician experience.

Prophylaxis competitors

13. Financial Position, Cash Burn and Dilution

Pharvaris reported €247 million in cash and cash equivalents at March 31, 2026, down from €292 million at December 31, 2025. First-quarter research and development expense was approximately €30.2 million, general and administrative expense was approximately €14.1 million and net loss was approximately €39.2 million.

In May 2026, the company sold 4,455,863 ordinary shares, including the underwriters’ full option, at $29.68 per share. Gross proceeds were approximately $132.3 million before fees and offering expenses. Management stated that the financing extended cash runway into 2028.

Share-count discipline

The May 2026 prospectus supplement projected 69,666,453 ordinary shares outstanding after full exercise of the underwriters’ option. That figure excluded 3,951,032 shares issuable upon exercise of options and 1,417,632 shares issuable upon vesting of restricted stock units outstanding as of December 31, 2025. Investors should therefore use a current fully diluted share count—not a stale basic count—when calculating market capitalization or per-share value.

Stock-based compensation and equity incentives are normal for biotechnology companies but remain a real economic cost. Any valuation model should use a fully diluted share count and should not assume that current cash lasts indefinitely. A positive CHAPTER-3 readout could improve financing flexibility; it could also create an opportunity for the company to raise more capital from strength.

14. Valuation Context: What the Market Is Already Paying For

PHVS traded around the low-to-mid $30s during July 2026, with third-party market-data services indicating an equity value of roughly $2.3–2.5 billion depending on the date and share-count methodology. This is not a distressed micro-cap valuation. The market already recognizes the positive RAPIDe-3 result, the accepted NDA, the Q3 CHAPTER-3 catalyst and the strengthened balance sheet.

That valuation changes the question. Investors are not merely deciding whether deucrictibant works. They are deciding whether the combined on-demand and prophylaxis franchise can become large enough to justify a multi-billion-dollar pre-revenue value after accounting for development risk, launch spending and competition.

A practical sum-of-the-parts framework

A third-party aggregation checked on July 24, 2026 showed a broad range of analyst price targets, approximately $30 to $74, with an average near $50. These are third-party opinions, not company guidance and not Merlintrader targets. The wide range reflects different assumptions about CHAPTER-3 probability, peak sales, competition and discount rates. Investors should not treat consensus as evidence that the current price is cheap.

15. Ownership, Short Interest and Analyst Coverage

Pharvaris has substantial specialist institutional ownership. Its 2025 annual report identified several holders above the 5% reporting threshold, and third-party ownership aggregators list investors such as General Atlantic, Foresite, venBio, FMR, Bain Capital Life Sciences, Deerfield and Commodore among major historical holders. Ownership data can lag and should be verified through current Schedule 13D/13G and Form 13F filings.

High-quality healthcare ownership can support credibility and liquidity, but concentrated sponsorship can also amplify volatility. Large funds may rebalance around a binary catalyst, lock in gains after positive data or reduce risk before a readout. A strong shareholder list is not a substitute for clinical evidence.

Short interest

Official Nasdaq data for the June 30, 2026 settlement date showed 985,973 PHVS shares sold short with 2.27 days to cover. By the July 15, 2026 settlement date the position had risen to 1,136,733 shares with 1.68 days to cover. Nasdaq does not publish a percentage of float; measured against the roughly 69.7 million shares outstanding after the May offering, the mid-July position is close to 1.6%. That is not an unusually crowded short position for a catalyst-driven biotech. A positive result can still produce short covering, but the setup should not be framed primarily as a squeeze thesis.

Sell-side coverage

The company’s Investor Relations page lists coverage from BofA Securities, Cantor, Citizens, Guggenheim, H.C. Wainwright, JonesResearch, KBC Securities, Leerink Partners, Morgan Stanley, Oppenheimer, RBC Capital Markets, Van Lanschot Kempen, Wedbush and Wolfe Research. Analyst opinions belong to the firms and do not represent Pharvaris or Merlintrader.

16. Management, Board and Execution Capability

Berndt Modig serves as Chief Executive Officer. Peng Lu, M.D., Ph.D., serves as President and has held senior medical and development responsibilities. Anne Lesage, Ph.D., leads early development and contributes to the company’s bradykinin biology strategy. David Nassif serves as Chief Financial Officer. The broader team includes executives with rare-disease and HAE development experience.

Management deserves credit for recovering from the prior U.S. clinical holds, completing RAPIDe-3, enrolling CHAPTER-3, submitting the NDA and raising capital before the most important near-term readout. Those achievements demonstrate execution. The next phase is different: building a commercial organization, validating manufacturing, negotiating payer access and managing two potential product launches requires capabilities beyond clinical development.

Governance points to monitor

• Executive compensation and equity-award growth relative to milestones.
• Insider selling or option exercises around major events.
• Board independence and rare-disease commercialization expertise.
• Capital allocation between launch preparation, CREAATE and speculative expansion.
• Whether management communicates full datasets rather than relying on promotional headline metrics.

17. Manufacturing, Supply Chain and Intellectual Property

Pharvaris relies on third-party contract development and manufacturing organizations. Its 2025 annual report described two CDMOs for active pharmaceutical ingredient production, separate partners for the IR capsules and XR tablets, and additional organizations for packaging, labeling and distribution. This is a common biotechnology model, but the company does not control the facilities directly.

The company reported that it had established a scalable synthetic route and that raw materials could be sourced from multiple suppliers. The intended commercial formulations are already being used in the pivotal and filing programs, which reduces but does not eliminate comparability risk.

CMC remains a major regulatory risk

Many late-stage biotechnology applications fail or are delayed for manufacturing rather than efficacy. The FDA will evaluate process validation, stability, impurities, packaging, supplier controls and inspection findings. Because the IR and XR products use different formulations and manufacturing partners, each has its own CMC package even though the active ingredient is shared.

Patent estate

As of December 31, 2025, Pharvaris reported ownership of five U.S. patents and approximately 150 national or regional patents, plus 85 pending applications worldwide. The portfolio included composition-of-matter claims, methods of use and formulation claims. The company stated that relevant patents expire in 2038 or later before possible patent-term extensions or adjustments.

Composition-of-matter protection is the most important layer because it covers the molecule itself. Formulation and method patents can extend or reinforce protection but are often easier to challenge or design around. Orphan exclusivity and regulatory data exclusivity may provide additional protection if approval is obtained.

18. Pharvaris Catalyst Calendar

19. Bull, Mixed and Bear Scenarios

Scenario asymmetry

The downside is not necessarily zero because RAPIDe-3 and the accepted IR NDA retain value. However, a CHAPTER-3 failure would remove the part of the thesis that most clearly differentiates Pharvaris as an integrated franchise. The share-price reaction will depend on how much prophylaxis value the market has embedded immediately before the data.

20. Risk Register and Monitoring Checklist

Pre-catalyst checklist

• Confirm that CHAPTER-3 data have not already been released.
• Record the latest market capitalization and fully diluted share count.
• Review any new SEC filing, financing or insider transaction.
• Check competitor news from KalVista, BioCryst, Takeda, Ionis and CSL.
• Verify whether the company has narrowed the Q3 window.
• Separate company claims from independently published or regulator-reviewed evidence.
• Define in advance what attack rate, attack-free percentage and safety profile would qualify as strong, mixed or weak.

21. How to Read the CHAPTER-3 Press Release

Biotechnology press releases are designed to emphasize the strongest interpretation. Investors should reconstruct the result methodically.

A headline such as “met the primary endpoint” is insufficient. A commercially strong result should show that patients experience few attacks, remain on therapy and avoid rescue treatment. If the release emphasizes only relative reductions, trademarked endpoints or selected subgroups while delaying absolute rates and safety details, caution is appropriate.